There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

Despite these benefits, the hallucinogenic actions of these drugs at the serotonin 2A receptor (5-HT2AR) limit their clinical use in diverse settings. Activation of the 5-HT2AR can stimulate both G ...

This study suggests that immunotherapy may not be the optimal ... New, Rare Type of Small Cell Lung Cancer Identified Sep. 11, 2024 — A team of doctors and researchers have identified a new ...

Furthermore, the treatment of FMF does not entail expensive, difficult, or esoteric enzyme replacement, recombinant gene therapy, specialized diet, or synthesized small molecular ligand inhibitor ...